Table 2.
Group | Masson (%)∇ | Wnt1 | β-catenin | GSK-3β | Dkk1 | TCF4 | Fn1 |
---|---|---|---|---|---|---|---|
Sham | 5.1±0.4 | 3.31±0.69 | 1.05±0.08 | 4.0±0.7 | 0.42±0.06 | 2.5±0.1 | 2.60±0.44 |
BC | 5.3±0.3 | 3.37±0.04 | 1.45±0.83 | 2.7±0.4 | 0.35±0.06 | 2.2±0.1 | 2.90±0.55 |
5/6 Nx | 15.8±1.4# | 8.92±0.88# | 4.99±1.00# | 8.9±1.1# | 4.70±0.12# | 11.2±1.2# | 6.71±0.38# |
Losartan | 10.9±1.7#,* | 8.76±1.54# | 3.50±0.35#,* | 8.3±1.3# | 4.29±0.70 | 6.7±0.3#,* | 5.26±0.11#,* |
UCG | 9.9±0.8#,* | 6.70±0.41#,* | 2.54±0.62#,* | 7.0±1.4#,* | 3.69±0.68 | 4.3±0.3#,* | 5.36±0.17#,* |
HGF-L | 8.1±0.5#,*,Δ | 6.34±0.24#,*,Δ | 2.97±0.82#,* | 6.3±0.5#,* | 3.78±1.15 | 6.7±0.5#,* | 5.56±0.37#,* |
HGF-M | 7.3±0.9#,*,Δ | 5.95±1.11#,*,Δ | 2.49±0.57#,* | 7.0±1.4#,* | 4.96±1.46 | 6.4±0.5#,* | 4.72±0.70#,* |
HGF-H | 5.6±1.2*,Δ | 4.32±0.22*,Δ | 1.83±0.16*,Δ | 8.8±0.4# | 6.62±1.03 | 6.0±0.5#,* | 4.16±0.49#,*,Δ |
Notes: All data are showed after multiplying by 102. Compared with Sham and BC groups,
P<0.05; compared with the 5/6 Nx group,
P<0.05; and compared with the losartan group,
P<0.05.
the proportion of positive area.
Abbreviations: GSK, glycogen synthase kinase; Dkk1, dickkopf 1; TCF4, transcription factor 4; Fn1, fibronectin 1; Sham, sham-operated group; BC, background control group; Nx, 5/6 nephrectomy; UCG, uremic clearance granule; HGF-L, Huang Gan formula low dose group; HGF-M, Huang Gan formula middle dose group; HGF-H, Huang Gan formula high dose group.